≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback
info icon

This is a non-core endpoint: only basic statistics are computed.

Upper arm

DOID Endpoint Browser

Z21_UPPER_ARM

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — ZA2.0
  • Cause of death: ICD-10 — ZA2.0

2 out of 7 registries used, show all original rules.

88

4. Check minimum number of events

None

88

5. Include endpoints

None

88

6. Filter based on genotype QC (FinnGen only)

85

Control definitions (FinnGen only)

Control exclude
Z21_ADDIT_CODES_LOCAT_DEFECT_INJURY_ILLNE

Extra metadata

Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF4
Parent code in ICD-10
Z[AB]

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

This endpoint is excluded from FinRegistry analyses (omitted endpoint).

-FinnGen-

Key figures

All Female Male
Number of individuals 85 43 42
Unadjusted period prevalence (%) 0.02 0.02 0.02
Median age at first event (years) 55.73 51.98 59.57

-FinnGen-

Age distribution of first events

-FinnGen-

Year distribution of first events

-FinnGen-

Cumulative Incidence Function

Not a core endpoint, no data to show.

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
88
Matched controls
880
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
ZA2.0
ICD-10 Finland
Upper arm
+∞
124.8
88
*
NC1AA
NOMESCO Finland
Elbow X-ray examination without contrast
15.8
13.0
21
17
W01
ICD-10 Finland
Fall on same level from slipping, tripping and stumbling
3.3
6.8
39
172

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Orthopedic Surgery
20 [38004465]
1.1e+00
1.4e+00
1.6e+00
—
3.2e+00
1.6e+00
7.5e-01
cases:34.48%
controls:15.14%
cases:19.54%
controls:5.78%
cases:5.75%
controls:1.16%
—
—
cases:19.54%
controls:0.93%
cases:21.18%
controls:5.19%
cases:25.00%
controls:13.63%
30
131
57
734
17
50
70
815
5
10
82
855
—
17
8
70
856
18
43
67
786
17
92
51
583
Outpatient Visit
OP [9202]
5.4e-01
4.3e-01
3.1e-01
4.0e+00
9.6e-01
8.9e-01
4.8e-01
cases:86.21%
controls:78.50%
cases:64.37%
controls:53.99%
cases:16.09%
controls:12.37%
cases:24.14%
controls:0.58%
cases:25.29%
controls:11.46%
cases:71.76%
controls:51.03%
cases:89.71%
controls:84.30%
75
679
12
186
56
467
31
398
14
107
73
758
21
5
66
860
22
99
65
765
61
423
24
406
61
569
7
106
Case Management Agency
251B00000X [38004193]
2.4e-01
1.1e-01
4.3e-01
3.4e+00
9.8e-01
5.7e-01
3.3e-01
cases:83.91%
controls:80.35%
cases:73.56%
controls:71.33%
cases:39.08%
controls:29.48%
cases:44.83%
controls:2.66%
cases:50.57%
controls:27.78%
cases:83.53%
controls:74.07%
cases:94.12%
controls:92.00%
73
695
14
170
64
617
23
248
34
255
53
610
39
23
48
842
44
240
43
624
71
614
14
215
64
621
4
54
Fall on same level from slipping, tripping and stumbling
W01 [45756243]
1.3e+00
—
—
—
1.0e+50
1.9e+00
1.1e+00
cases:13.79%
controls:4.16%
—
—
—
—
—
—
cases:5.75%
controls:0.00%
cases:8.24%
controls:1.33%
cases:13.24%
controls:4.89%
12
36
75
829
—
—
—
5
0
82
864
7
11
78
818
9
33
59
642
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
1.4e-01
3.4e-01
2.2e-01
3.0e+00
6.6e-01
2.8e-01
7.9e-01
cases:42.53%
controls:39.08%
cases:36.78%
controls:29.36%
cases:8.05%
controls:6.59%
cases:10.34%
controls:0.58%
cases:12.64%
controls:6.94%
cases:37.65%
controls:31.24%
cases:75.00%
controls:57.63%
37
338
50
527
32
254
55
611
7
57
80
808
9
5
78
860
11
60
76
804
32
259
53
570
51
389
17
286
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
1.2e-01
3.6e-01
2.3e-01
3.0e+00
6.8e-01
3.0e-01
6.8e-01
cases:41.38%
controls:38.61%
cases:36.78%
controls:28.90%
cases:8.05%
controls:6.47%
cases:10.34%
controls:0.58%
cases:12.64%
controls:6.83%
cases:37.65%
controls:31.00%
cases:72.06%
controls:56.74%
36
334
51
531
32
250
55
615
7
56
80
809
9
5
78
860
11
59
76
805
32
257
53
572
49
383
19
292
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
1.9e-01
2.8e-01
2.0e-01
3.0e+00
4.4e-01
2.3e-01
7.0e-01
cases:47.13%
controls:42.43%
cases:41.38%
controls:34.80%
cases:9.20%
controls:7.63%
cases:10.34%
controls:0.58%
cases:12.64%
controls:8.56%
cases:41.18%
controls:35.71%
cases:76.47%
controls:61.78%
41
367
46
498
36
301
51
564
8
66
79
799
9
5
78
860
11
74
76
790
35
296
50
533
52
417
16
258
Supplier / Service Provider
OMOP5117446 [33004]
-5.5e-01
—
—
—
—
—
2.9e+00
cases:17.24%
controls:26.47%
—
—
—
—
—
—
—
—
—
—
cases:19.12%
controls:1.33%
15
229
72
636
—
—
—
—
—
13
9
55
666
Influenza virus B RNA [Presence] in Nasopharynx by NAA with probe detection
76080-1 [46235759]
-1.0e+50
—
—
—
—
—
2.7e+00
cases:0.00%
controls:0.81%
—
—
—
—
—
—
—
—
—
—
cases:11.76%
controls:0.89%
0
7
87
858
—
—
—
—
—
8
6
60
669
Respiratory syncytial virus RNA [Presence] in Specimen by NAA with probe detection
40988-8 [3044254]
-1.0e+50
—
—
—
—
—
2.7e+00
cases:0.00%
controls:0.81%
—
—
—
—
—
—
—
—
—
—
cases:11.76%
controls:0.89%
0
7
87
858
—
—
—
—
—
8
6
60
669
Pharmacy visit
OMOP4822462 [581458]
1.0e+50
6.2e-01
5.6e-01
1.9e+00
8.2e-01
1.2e+00
1.4e+00
cases:100.00%
controls:95.61%
cases:91.95%
controls:86.01%
cases:60.92%
controls:47.17%
cases:12.64%
controls:2.20%
cases:67.82%
controls:48.03%
cases:95.29%
controls:86.37%
cases:98.53%
controls:94.22%
87
827
0
38
80
744
7
121
53
408
34
457
11
19
76
846
59
415
28
449
81
716
4
113
67
636
1
39
Rotator cuff syndrome
M75.1 [45596678]
6.0e-01
1.8e+00
—
—
2.5e+00
1.4e+00
—
cases:5.75%
controls:3.24%
cases:6.90%
controls:1.16%
—
—
—
—
cases:6.90%
controls:0.58%
cases:5.88%
controls:1.57%
—
—
5
28
82
837
6
10
81
855
—
—
6
5
81
859
5
13
80
816
—
Inpatient Hospital
21 [8717]
3.4e-01
5.3e-01
—
—
2.5e+00
2.7e-01
3.3e-01
cases:35.63%
controls:28.32%
cases:12.64%
controls:7.86%
—
—
—
—
cases:8.05%
controls:0.69%
cases:8.24%
controls:6.39%
cases:23.53%
controls:18.07%
31
245
56
620
11
68
76
797
—
—
7
6
80
858
7
53
78
776
16
122
52
553
Emergency Room Visit
ER [9203]
7.2e-01
4.7e-01
—
—
2.4e+00
4.2e-01
5.9e-01
cases:50.57%
controls:33.18%
cases:18.39%
controls:12.37%
—
—
—
—
cases:9.20%
controls:0.93%
cases:15.29%
controls:10.62%
cases:39.71%
controls:26.81%
44
287
43
578
16
107
71
758
—
—
8
8
79
856
13
88
72
741
27
181
41
494
Ankle X-ray examination without contrast
NH1AA [2001308235]
—
—
—
—
—
—
2.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.82%
controls:0.89%
—
—
—
—
—
—
6
6
62
669
epinephrine; parenteral
C01CA24 [21600303]
—
—
—
—
—
—
2.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.35%
controls:0.74%
—
—
—
—
—
—
5
5
63
670
Contusion of knee
S80.0 [45569633]
-1.0e+50
—
—
—
—
—
2.4e+00
cases:0.00%
controls:0.69%
—
—
—
—
—
—
—
—
—
—
cases:7.35%
controls:0.74%
0
6
87
859
—
—
—
—
—
5
5
63
670
epinephrine
S01EA01 [21603673]
—
—
—
—
—
—
2.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.35%
controls:0.74%
—
—
—
—
—
—
5
5
63
670
Shoulder symptom/complaint
L08 [2002000632]
—
—
—
—
—
2.3e+00
1.1e+00
—
—
—
—
—
—
—
—
—
—
cases:8.24%
controls:0.84%
cases:13.24%
controls:5.04%
—
—
—
—
—
7
7
78
822
9
34
59
641
Bacteria identified in Skin by Aerobe culture
620-5 [3007853]
—
2.3e+00
—
—
—
—
—
—
—
cases:5.75%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
5
5
82
860
—
—
—
—
—
Other general examinations
Z00.8 [45581001]
2.3e+00
—
—
—
—
—
—
cases:5.75%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
—
5
5
82
860
—
—
—
—
—
—
Laboratory Visit
OMOP4822461 [32036]
-4.0e-02
3.2e-01
2.9e-01
2.3e+00
2.5e-01
3.4e-01
4.9e-01
cases:52.87%
controls:53.87%
cases:55.17%
controls:47.28%
cases:21.84%
controls:17.23%
cases:13.79%
controls:1.50%
cases:21.84%
controls:17.94%
cases:58.82%
controls:50.30%
cases:85.29%
controls:78.07%
46
466
41
399
48
409
39
456
19
149
68
716
12
13
75
852
19
155
68
709
50
417
35
412
58
527
10
148
Emergency Medicine
93 [38004510]
7.2e-01
8.4e-01
—
—
2.3e+00
8.2e-01
7.3e-01
cases:29.89%
controls:17.23%
cases:19.54%
controls:9.48%
—
—
—
—
cases:9.20%
controls:1.04%
cases:20.00%
controls:9.89%
cases:47.06%
controls:30.07%
26
149
61
716
17
82
70
783
—
—
8
9
79
855
17
82
68
747
32
203
36
472
cefalexin; oral
J01DB01 [21602870]
5.6e-01
-3.3e-01
2.1e+00
—
—
5.0e-01
7.8e-01
cases:43.68%
controls:30.64%
cases:6.90%
controls:9.36%
cases:6.90%
controls:0.92%
—
—
—
—
cases:15.29%
controls:9.89%
cases:41.18%
controls:24.30%
38
265
49
600
6
81
81
784
6
8
81
857
—
—
13
82
72
747
28
164
40
511
Creatine kinase.MB [Mass/volume] in Serum or Plasma
13969-1 [3005785]
-1.0e+50
—
—
—
—
—
2.0e+00
cases:0.00%
controls:2.20%
—
—
—
—
—
—
—
—
—
—
cases:13.24%
controls:1.93%
0
19
87
846
—
—
—
—
—
9
13
59
662
Removal of sutures
SPAT1153 [2001700254]
4.6e-01
9.0e-01
—
—
—
2.0e+00
3.0e-01
cases:9.20%
controls:6.01%
cases:5.75%
controls:2.43%
—
—
—
—
—
—
cases:9.41%
controls:1.33%
cases:8.82%
controls:6.67%
8
52
79
813
5
21
82
844
—
—
—
8
11
77
818
6
45
62
630
Intravenous general anesthesia
WX404 [2001310807]
-1.0e+50
—
—
—
—
—
2.0e+00
cases:0.00%
controls:3.35%
—
—
—
—
—
—
—
—
—
—
cases:10.29%
controls:1.48%
0
29
87
836
—
—
—
—
—
7
10
61
665
Hand Surgery
40 [38004480]
—
1.8e+00
—
—
—
2.0e+00
9.6e-01
—
—
cases:5.75%
controls:1.04%
—
—
—
—
—
—
cases:8.24%
controls:1.21%
cases:8.82%
controls:3.56%
—
5
9
82
856
—
—
—
7
10
78
819
6
24
62
651
Simple examination of mouth
SAA01 [2001310274]
1.8e-01
4.9e-01
1.9e+00
—
—
6.4e-01
7.9e-01
cases:34.48%
controls:30.52%
cases:21.84%
controls:14.57%
cases:9.20%
controls:1.50%
—
—
—
—
cases:24.71%
controls:14.72%
cases:50.00%
controls:31.26%
30
264
57
601
19
126
68
739
8
13
79
852
—
—
21
122
64
707
34
211
34
464
General Surgery
2 [38004447]
2.5e-01
1.8e+00
—
1.0e+50
—
1.0e+00
9.6e-01
cases:18.39%
controls:14.91%
cases:14.94%
controls:2.77%
—
—
cases:21.84%
controls:0.00%
—
—
cases:10.59%
controls:3.98%
cases:23.53%
controls:10.52%
16
129
71
736
13
24
74
841
—
19
0
68
865
—
9
33
76
796
16
71
52
604
paracetamol; oral, parenteral, rectal
N02BE01 [21604344]
3.0e-01
7.0e-01
2.6e-01
—
1.7e+00
3.9e-01
6.0e-01
cases:48.28%
controls:40.92%
cases:35.63%
controls:21.62%
cases:5.75%
controls:4.51%
—
—
cases:18.39%
controls:4.05%
cases:29.41%
controls:21.95%
cases:61.76%
controls:46.96%
42
354
45
511
31
187
56
678
5
39
82
826
—
16
35
71
829
25
182
60
647
42
317
26
358
ibuprofen
R02AX02 [1588667]
2.6e-01
3.3e-01
1.0e+00
—
1.7e+00
6.4e-01
6.1e-01
cases:47.13%
controls:40.81%
cases:22.99%
controls:17.69%
cases:6.90%
controls:2.54%
—
—
cases:12.64%
controls:2.66%
cases:28.24%
controls:17.25%
cases:50.00%
controls:35.11%
41
353
46
512
20
153
67
712
6
22
81
843
—
11
23
76
841
24
143
61
686
34
237
34
438
ibuprofen; oral, parenteral, rectal
M01AE01 [21603967]
2.6e-01
3.3e-01
1.0e+00
—
1.7e+00
6.4e-01
6.1e-01
cases:47.13%
controls:40.81%
cases:22.99%
controls:17.69%
cases:6.90%
controls:2.54%
—
—
cases:12.64%
controls:2.66%
cases:28.24%
controls:17.25%
cases:50.00%
controls:35.11%
41
353
46
512
20
153
67
712
6
22
81
843
—
11
23
76
841
24
143
61
686
34
237
34
438
Extraction of tooth
EBA00 [2001301923]
-1.7e-01
—
—
—
—
1.6e+00
1.0e+00
cases:6.90%
controls:8.09%
—
—
—
—
—
—
—
—
cases:10.59%
controls:2.29%
cases:19.12%
controls:8.00%
6
70
81
795
—
—
—
—
9
19
76
810
13
54
55
621
clindamycin; oral, parenteral
J01FF01 [21602985]
7.3e-01
—
—
—
—
—
1.6e+00
cases:8.05%
controls:4.05%
—
—
—
—
—
—
—
—
—
—
cases:14.71%
controls:3.41%
7
35
80
830
—
—
—
—
—
10
23
58
652
combinations of corticosteroids
D07XB30 [21602188]
4.4e-02
5.6e-01
—
—
—
1.5e+00
4.8e-01
cases:10.34%
controls:9.94%
cases:5.75%
controls:3.35%
—
—
—
—
—
—
cases:11.76%
controls:2.90%
cases:17.65%
controls:11.70%
9
86
78
779
5
29
82
836
—
—
—
10
24
75
805
12
79
56
596
combinations of corticosteroids
D07AB30 [21602118]
4.4e-02
5.6e-01
—
—
—
1.5e+00
4.8e-01
cases:10.34%
controls:9.94%
cases:5.75%
controls:3.35%
—
—
—
—
—
—
cases:11.76%
controls:2.90%
cases:17.65%
controls:11.70%
9
86
78
779
5
29
82
836
—
—
—
10
24
75
805
12
79
56
596
Counselling related to known health issue
SPAT1310 [2001700411]
1.7e-01
—
—
—
—
8.8e-01
1.4e+00
cases:9.20%
controls:7.86%
—
—
—
—
—
—
—
—
cases:5.88%
controls:2.53%
cases:25.00%
controls:7.26%
8
68
79
797
—
—
—
—
5
21
80
808
17
49
51
626
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
3.6e-01
4.4e-01
7.1e-01
—
1.3e+00
1.5e-01
8.7e-01
cases:44.83%
controls:36.18%
cases:31.03%
controls:22.43%
cases:11.49%
controls:6.01%
—
—
cases:13.79%
controls:4.05%
cases:23.53%
controls:20.87%
cases:72.06%
controls:51.85%
39
313
48
552
27
194
60
671
10
52
77
813
—
12
35
75
829
20
173
65
656
49
350
19
325
Troponin I.cardiac [Mass/volume] in Serum or Plasma
10839-9 [3021337]
6.8e-01
1.4e+00
—
—
—
1.2e+00
1.2e+00
cases:9.20%
controls:4.86%
cases:6.90%
controls:1.73%
—
—
—
—
—
—
cases:8.24%
controls:2.65%
cases:22.06%
controls:7.70%
8
42
79
823
6
15
81
850
—
—
—
7
22
78
807
15
52
53
623
hydrocortisone
D07AA02 [21602102]
2.2e-01
—
—
—
—
—
1.2e+00
cases:10.34%
controls:8.44%
—
—
—
—
—
—
—
—
—
—
cases:19.12%
controls:6.81%
9
73
78
792
—
—
—
—
—
13
46
55
629
hydrocortisone buteprate
D07AB11 [21602115]
2.2e-01
—
—
—
—
—
1.2e+00
cases:10.34%
controls:8.44%
—
—
—
—
—
—
—
—
—
—
cases:19.12%
controls:6.81%
9
73
78
792
—
—
—
—
—
13
46
55
629
hydrocortisone aceponate
D07AC16 [21602135]
2.2e-01
—
—
—
—
—
1.2e+00
cases:10.34%
controls:8.44%
—
—
—
—
—
—
—
—
—
—
cases:19.12%
controls:6.81%
9
73
78
792
—
—
—
—
—
13
46
55
629
hydrocortisone
C05AA01 [21601608]
2.2e-01
—
—
—
—
—
1.2e+00
cases:10.34%
controls:8.44%
—
—
—
—
—
—
—
—
—
—
cases:19.12%
controls:6.81%
9
73
78
792
—
—
—
—
—
13
46
55
629
hydrocortisone butyrate
D07AB02 [21602106]
2.2e-01
—
—
—
—
—
1.2e+00
cases:10.34%
controls:8.44%
—
—
—
—
—
—
—
—
—
—
cases:19.12%
controls:6.81%
9
73
78
792
—
—
—
—
—
13
46
55
629
hydrocortisone
A07EA02 [21600654]
2.2e-01
—
—
—
—
—
1.2e+00
cases:10.34%
controls:8.44%
—
—
—
—
—
—
—
—
—
—
cases:19.12%
controls:6.81%
9
73
78
792
—
—
—
—
—
13
46
55
629
prednisolone; oral, parenteral
H02AB06 [21602734]
1.1e+00
6.8e-01
—
—
—
7.4e-01
4.7e-01
cases:25.29%
controls:10.29%
cases:9.20%
controls:4.86%
—
—
—
—
—
—
cases:9.41%
controls:4.70%
cases:19.12%
controls:12.89%
22
89
65
776
8
42
79
823
—
—
—
8
39
77
790
13
87
55
588
prednisolone
A07EA01 [21600653]
1.1e+00
6.8e-01
—
—
—
7.2e-01
4.7e-01
cases:25.29%
controls:10.40%
cases:9.20%
controls:4.86%
—
—
—
—
—
—
cases:9.41%
controls:4.83%
cases:19.12%
controls:12.89%
22
90
65
775
8
42
79
823
—
—
—
8
40
77
789
13
87
55
588
General Practice
1 [38004446]
9.9e-01
3.8e-01
—
1.0e+50
—
4.7e-01
8.3e-01
cases:28.74%
controls:13.06%
cases:8.05%
controls:5.66%
—
—
cases:18.39%
controls:0.00%
—
—
cases:8.24%
controls:5.31%
cases:27.94%
controls:14.52%
25
113
62
752
7
49
80
816
—
16
0
71
865
—
7
44
78
785
19
98
49
577
Infiltration anesthesia
WX110 [2001310767]
9.8e-02
9.2e-01
1.8e+00
—
—
8.5e-01
9.2e-01
cases:27.59%
controls:25.66%
cases:18.39%
controls:8.21%
cases:6.90%
controls:1.16%
—
—
—
—
cases:18.82%
controls:9.05%
cases:47.06%
controls:26.07%
24
222
63
643
16
71
71
794
6
10
81
855
—
—
16
75
69
754
32
176
36
499
influenza, inactivated, split virus or surface antigen
J07BB02 [21601335]
1.9e-02
5.2e-02
-1.0e+50
—
-1.0e+50
-2.4e-02
-5.5e-02
cases:22.99%
controls:22.66%
cases:19.54%
controls:18.73%
cases:0.00%
controls:3.24%
—
—
cases:0.00%
controls:1.39%
cases:20.00%
controls:20.39%
cases:39.71%
controls:41.04%
20
196
67
669
17
162
70
703
0
28
87
837
—
0
12
87
852
17
169
68
660
27
277
41
398
Mycoplasma pneumoniae Ab [Presence] in Serum by Immunoassay
5253-0 [3027545]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
87
860
—
—
—
—
—
—
Paralysis/weakness
N18 [2002000729]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
87
860
—
—
—
—
—
—
beclometasone; nasal
R01AD01 [21605043]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
0
5
87
860
—
—
—
—
—
Cytomegalovirus IgG Ab [Titer] in Serum or Plasma
22246-3 [3017918]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.89%
—
—
—
—
—
—
0
6
68
669
letrozole; oral
L02BG04 [21603842]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.16%
cases:0.00%
controls:0.81%
—
—
—
—
—
—
—
—
—
—
0
10
87
855
0
7
87
858
—
—
—
—
—
Carpal tunnel syndrome
G56.0 [45566891]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
87
854
—
—
—
—
—
—
Subjective visual disturbances
H53.1 [45557467]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.81%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
87
858
—
—
—
—
—
—
Dorsalgia, unspecified
M54.9 [45538791]
1.7e+00
—
—
—
—
—
—
cases:6.90%
controls:1.39%
—
—
—
—
—
—
—
—
—
—
—
—
6
12
81
853
—
—
—
—
—
—
Person consulting for explanation of investigation findings
Z71.2 [45552100]
4.0e-01
—
—
—
-1.0e+50
—
5.2e-01
cases:6.90%
controls:4.74%
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
cases:10.29%
controls:6.37%
6
41
81
824
—
—
—
0
5
87
859
—
7
43
61
632
prednisolone
S01BA04 [21603621]
7.2e-01
—
—
—
—
—
—
cases:5.75%
controls:2.89%
—
—
—
—
—
—
—
—
—
—
—
—
5
25
82
840
—
—
—
—
—
—
Obesity due to excess calories
E66.01 [2000501501]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.69%
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
0
6
87
859
—
—
—
0
9
85
820
—
Besnier prurigo
L20.0 [45562534]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.16%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
0
10
87
855
—
—
—
—
0
6
85
823
—
Palpitations
R00.2 [45558446]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.04%
—
—
—
—
—
—
0
7
68
668
tretinoin, combinations; ointment
D10AD51 [21602298]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
87
860
—
—
—
—
—
—
Neutrophil cytoplasmic Ab [Units/volume] in Serum
5128-4 [3001334]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.33%
—
—
—
—
—
—
0
9
68
666
Influenza virus A Ag [Presence] in Specimen
31859-2 [3002523]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
87
860
—
—
—
—
—
—
insulin (beef); parenteral
A10AD02 [21600730]
6.0e-01
—
—
—
—
—
—
cases:5.75%
controls:3.24%
—
—
—
—
—
—
—
—
—
—
—
—
5
28
82
837
—
—
—
—
—
—
Cardiovascular stress test using bicycle ergometer
26046004 [4094501]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.74%
—
—
—
—
—
—
0
5
68
670
Radiological examination, not elsewhere classified
Z01.6 [45605096]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.35%
controls:0.89%
—
—
—
—
—
—
5
6
63
669
Cytomegalovirus DNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection
72493-0 [43055120]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.74%
—
—
—
—
—
—
0
5
68
670
Knee and lower leg MRI examination with high intensity magnet
NG1BG [2001308056]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
87
860
—
—
—
—
—
—
FEV1/FVC --post bronchodilation
69970-2 [42868459]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
—
0
6
85
823
—
IgA [Mass/volume] in Serum or Plasma
2458-8 [3007164]
1.8e-01
-1.0e+50
—
—
—
—
2.8e-01
cases:5.75%
controls:4.86%
cases:0.00%
controls:1.73%
—
—
—
—
—
—
—
—
cases:8.82%
controls:6.81%
5
42
82
823
0
15
87
850
—
—
—
—
6
46
62
629
Familial hypercholesterolaemia
E78.00 [2000501513]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.89%
—
—
—
—
—
—
0
6
68
669
tiotropium bromide; inhalant
R03BB04 [21603296]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
0
5
87
860
—
—
—
—
Pregnancy associated plasma protein A [Units/volume] in Serum or Plasma
32046-5 [3021584]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
87
860
—
—
—
—
—
—
Chronic apical periodontitis
K04.5 [45586691]
—
—
—
—
—
1.9e+00
1.3e+00
—
—
—
—
—
—
—
—
—
—
cases:7.06%
controls:1.09%
cases:14.71%
controls:4.59%
—
—
—
—
—
6
9
79
820
10
31
58
644
Outcome of delivery
Z37 [45581024]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.69%
—
—
—
—
—
—
—
—
—
—
—
0
6
87
859
—
—
—
—
—
Foreign body in skin
S15 [2002000980]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.74%
—
—
—
—
—
—
0
5
68
670
Endomysium IgG Ab [Titer] in Serum
49726-3 [3032773]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
87
860
—
—
—
—
—
—
Short blood count panel - Blood
55429-5 [40758558]
—
—
—
—
—
1.0e+00
3.7e-01
—
—
—
—
—
—
—
—
—
—
cases:7.06%
controls:2.65%
cases:11.76%
controls:8.44%
—
—
—
—
—
6
22
79
807
8
57
60
618
Extensive CT examination of arteria pulmonalis
FB1BD [2001302407]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.04%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.04%
0
9
87
856
—
—
—
—
—
0
7
68
668
Sick sinus syndrome
I49.5 [45562354]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.74%
—
—
—
—
—
—
0
5
68
670
Pustulosis palmaris et plantaris
L40.3 [45591634]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.74%
—
—
—
—
—
—
0
5
68
670
glycerol; rectal
A06AG04 [21600587]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.81%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
87
858
—
—
—
—
—
—
CT of neck arteries
PA6AD [2001308692]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.89%
—
—
—
—
—
—
0
6
68
669
bisoprolol and thiazides
C07BB07 [21601714]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
87
860
—
—
—
—
—
—
fluocinolone acetonide and antiinfectives
S02CA05 [21605177]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.22%
—
—
—
—
—
—
0
15
68
660
Placement of prefabricated palatal or lingual arch
SJD40 [2001310441]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
87
860
—
—
—
—
—
—
salbutamol; inhalant
R03AC02 [21603256]
3.9e-01
6.9e-01
—
—
—
5.2e-01
7.3e-01
cases:24.14%
controls:17.69%
cases:14.94%
controls:8.09%
—
—
—
—
—
—
cases:14.12%
controls:8.93%
cases:30.88%
controls:17.78%
21
153
66
712
13
70
74
795
—
—
—
12
74
73
755
21
120
47
555
sildenafil; oral
G04BE03 [21602648]
—
—
—
—
—
—
6.7e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:11.76%
controls:6.37%
—
—
—
—
—
—
8
43
60
632
Prostate Specific Ag Free/Prostate specific Ag.total in Serum or Plasma
12841-3 [3001784]
1.1e-01
—
-1.0e+50
—
—
3.9e-02
-1.7e-01
cases:9.20%
controls:8.32%
—
—
cases:0.00%
controls:0.58%
—
—
—
—
cases:5.88%
controls:5.67%
cases:11.76%
controls:13.63%
8
72
79
793
—
0
5
87
860
—
—
5
47
80
782
8
92
60
583
Extensive angiography of hear and/or coronary arteries
FN1BC [2001303000]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.81%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
87
858
—
—
—
—
—
—
Other and unspecified abdominal pain
R10.4 [45568113]
1.1e+00
-1.0e+50
—
—
—
1.7e+00
8.8e-01
cases:12.64%
controls:4.62%
cases:0.00%
controls:1.97%
—
—
—
—
—
—
cases:7.06%
controls:1.33%
cases:13.24%
controls:5.93%
11
40
76
825
0
17
87
848
—
—
—
6
11
79
818
9
40
59
635
Prealbumin [Mass/volume] in Serum or Plasma
14338-8 [3013742]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.73%
—
—
—
—
—
—
—
—
—
—
—
—
0
15
87
850
—
—
—
—
—
—
Inpatient Visit
IP [9201]
1.7e-01
—
—
—
—
—
2.0e-01
cases:6.90%
controls:5.90%
—
—
—
—
—
—
—
—
—
—
cases:13.24%
controls:11.11%
6
51
81
814
—
—
—
—
—
9
75
59
600
Creatine kinase [Enzymatic activity/volume] in Serum or Plasma
2157-6 [3007220]
4.1e-02
—
—
—
—
—
8.0e-01
cases:8.05%
controls:7.75%
—
—
—
—
—
—
—
—
—
—
cases:19.12%
controls:9.63%
7
67
80
798
—
—
—
—
—
13
65
55
610
metformin; oral
A10BA02 [21600747]
-5.8e-01
-4.4e-01
—
—
—
-1.3e-01
-2.3e-01
cases:5.75%
controls:9.83%
cases:5.75%
controls:8.67%
—
—
—
—
—
—
cases:8.24%
controls:9.29%
cases:11.76%
controls:14.37%
5
85
82
780
5
75
82
790
—
—
—
7
77
78
752
8
97
60
578
Fetal Nuchal fold [Multiple of the median] Thickness adjusted for maternal weight
60477-7 [40763531]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.33%
—
—
—
—
—
—
0
9
68
666
olopatadine
R01AC08 [21605040]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.89%
—
—
—
—
—
—
0
6
68
669
Chronic ischaemic heart disease
I25 [45581765]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.84%
cases:0.00%
controls:1.63%
—
—
—
—
—
0
7
85
822
0
11
68
664
Retinal detachment with retinal break
H33.0 [45547857]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
87
860
—
—
—
—
—
—
Mycoplasma pneumoniae IgM Ab [Presence] in Serum by Immunoassay
5257-1 [3010521]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
87
860
—
—
—
—
—
—
Bicarbonate [Moles/volume] standard in Capillary blood
19231-0 [3004490]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.81%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.04%
0
7
87
858
—
—
—
—
—
0
7
68
668
Chron obstructive pulmonary disease
R95 [2002000960]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
87
860
—
—
—
—
—
—
Localized oedema
R60.0 [45597193]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
0
5
85
824
—
Generalized anxiety disorder
F41.1 [45571764]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.81%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
87
858
—
—
—
—
—
—
MCH [Entitic mass]
28539-5 [3035941]
1.5e-01
4.2e-01
2.5e-01
—
7.4e-01
3.0e-01
4.2e-01
cases:50.57%
controls:46.82%
cases:47.13%
controls:36.99%
cases:10.34%
controls:8.21%
—
—
cases:18.39%
controls:9.72%
cases:47.06%
controls:39.81%
cases:76.47%
controls:68.00%
44
405
43
460
41
320
46
545
9
71
78
794
—
16
84
71
780
40
330
45
499
52
459
16
216
SMOKING - SMOKE2: yes - SMOKE3: current - SMOKE5: current
SMOKING-1-1-1 [2002330115]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
87
860
—
—
—
—
—
—
dexamethasone and antiinfectives
S02CA06 [21605178]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.93%
—
—
—
—
—
—
0
13
68
662
Office Visit
OMOP4822458 [581477]
6.3e-01
—
—
—
—
—
8.9e-01
cases:16.09%
controls:9.25%
—
—
—
—
—
—
—
—
—
—
cases:11.76%
controls:5.19%
14
80
73
785
—
—
—
—
—
8
35
60
640
Angiography of heart and/or coronary arteries
FN1AC [2001302996]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
—
—
—
—
—
—
—
—
—
—
0
8
87
857
—
—
—
—
—
Colonoscopy Study observation
28023-0 [3022145]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.31%
—
—
—
—
—
—
—
—
—
—
—
—
0
20
87
845
—
—
—
—
—
—
covid-19, RNA-based vaccine
J07BN01 [954934]
1.5e-01
4.0e-01
—
—
—
-1.7e-02
6.9e-02
cases:17.24%
controls:15.14%
cases:14.94%
controls:10.52%
—
—
—
—
—
—
cases:11.76%
controls:11.94%
cases:39.71%
controls:38.07%
15
131
72
734
13
91
74
774
—
—
—
10
99
75
730
27
257
41
418
Plain photography of ocular fundus
CK2S4 [2001301455]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.69%
—
—
—
—
—
—
—
—
—
—
—
0
6
87
859
—
—
—
—
—
Other senile cataract
H25.8 [45605644]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
—
—
—
—
—
—
—
—
—
—
0
8
87
857
—
—
—
—
—
Lumbar epidural anesthesia
WX306 [2001310796]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.81%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
87
858
—
—
—
—
—
—
Bronchitis, not specified as acute or chronic
J40 [45572167]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.89%
—
—
—
—
—
—
0
6
68
669
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
3.9e-01
1.1e-01
-1.0e+50
—
—
4.3e-01
8.3e-02
cases:18.39%
controls:13.29%
cases:6.90%
controls:6.24%
cases:0.00%
controls:0.81%
—
—
—
—
cases:7.06%
controls:4.70%
cases:20.59%
controls:19.26%
16
115
71
750
6
54
81
811
0
7
87
858
—
—
6
39
79
790
14
130
54
545
Left sided colitis
K51.5 [45533604]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.69%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
87
859
—
—
—
—
—
—
travoprost
S01EE04 [21603713]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.92%
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
0
8
87
857
0
5
87
860
—
—
—
—
—
desloratadine; oral
R06AX27 [21603526]
3.1e-01
—
—
—
-1.0e+50
—
—
cases:8.05%
controls:6.01%
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
7
52
80
813
—
—
—
0
5
87
859
—
—
Ultrasound examination of upper part of abdomen
JN1AE [2001305517]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.92%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.93%
0
8
87
857
—
—
—
—
—
0
13
68
662
Treatment of chronic ulcer or burn
SPAT1148 [2001700249]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.81%
—
—
—
—
—
—
—
—
—
—
—
0
7
87
858
—
—
—
—
—
Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma
48065-7 [3051714]
—
—
—
—
—
—
7.2e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:11.76%
controls:6.07%
—
—
—
—
—
—
8
41
60
634
Glucose [Moles/volume] in Cerebral spinal fluid
14744-7 [3020044]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.89%
—
—
—
—
—
—
0
6
68
669
Home Visit
OMOP4822459 [581476]
3.6e-01
—
—
—
—
4.7e-01
-8.2e-03
cases:9.20%
controls:6.59%
—
—
—
—
—
—
—
—
cases:5.88%
controls:3.74%
cases:10.29%
controls:10.37%
8
57
79
808
—
—
—
—
5
31
80
798
7
70
61
605
Approximal wear
K03.00 [2000502665]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
0
5
87
860
—
—
—
0
6
85
823
—
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
1.4e-01
6.5e-01
-1.0e+50
—
—
—
5.1e-01
cases:14.94%
controls:13.29%
cases:11.49%
controls:6.36%
cases:0.00%
controls:1.27%
—
—
—
—
—
—
cases:29.41%
controls:20.00%
13
115
74
750
10
55
77
810
0
11
87
854
—
—
—
20
135
48
540
semaglutide; oral, parenteral
A10BJ06 [1501778]
-1.0e+50
-1.0e+50
—
—
-1.0e+50
-1.0e+50
—
cases:0.00%
controls:0.92%
cases:0.00%
controls:0.81%
—
—
—
—
cases:0.00%
controls:0.58%
cases:0.00%
controls:0.72%
—
—
0
8
87
857
0
7
87
858
—
—
0
5
87
859
0
6
85
823
—
Guidance concerning treatment of rash and skin
SPAT1156 [2001700257]
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
1.1e+00
cases:0.00%
controls:2.08%
—
—
—
—
—
—
cases:0.00%
controls:0.58%
cases:0.00%
controls:0.72%
cases:7.35%
controls:2.52%
0
18
87
847
—
—
—
0
5
87
859
0
6
85
823
5
17
63
658
haemophilus influenzae B and hepatitis B
J07CA08 [21601379]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.81%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
87
858
—
—
—
—
—
—
Bacteria [Presence] in Urine
87829-8 [36304419]
4.7e-01
—
-1.0e+50
—
—
8.1e-01
4.3e-01
cases:10.34%
controls:6.71%
—
—
cases:0.00%
controls:0.92%
—
—
—
—
cases:7.06%
controls:3.26%
cases:13.24%
controls:9.04%
9
58
78
807
—
0
8
87
857
—
—
6
27
79
802
9
61
59
614
Thoracal epidural anesthesia
WX302 [2001310795]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.74%
—
—
—
—
—
—
0
5
68
670
budesonide; inhalant
R03BA02 [21603285]
—
—
-1.0e+50
—
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.69%
—
—
cases:0.00%
controls:1.04%
—
—
—
—
—
—
0
6
87
859
—
0
9
87
855
—
—
Thrombin time
3243-3 [3036489]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.89%
—
—
—
—
—
—
0
6
68
669
Tympanometry
SPAT1044 [2001700145]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.69%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.74%
0
6
87
859
—
—
—
—
—
0
5
68
670
insulin glargine; parenteral
A10AE04 [21600739]
6.0e-01
—
—
—
—
—
—
cases:5.75%
controls:3.24%
—
—
—
—
—
—
—
—
—
—
—
—
5
28
82
837
—
—
—
—
—
—
Fall on and from stairs and steps
W10 [45756250]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.74%
—
—
—
—
—
—
0
5
68
670
scopolamine
A04AD01 [21600499]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
—
0
6
85
823
—
Eye discharge
F03 [2002000401]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
87
857
—
—
—
—
—
—
Pedal cyclist injured in other and unspecified transport accidents
V19 [45756225]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.74%
—
—
—
—
—
—
0
5
68
670
Epithelial cells [#/volume] in Urine
30383-4 [3000850]
—
—
—
—
—
—
6.4e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:13.24%
controls:7.41%
—
—
—
—
—
—
9
50
59
625
Result test/procedure
-60 [2002000131]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
87
860
—
—
—
—
—
—
Open wound of eyelid and periocular area
S01.1 [45602056]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
87
860
—
—
—
—
—
—
Follow-up examination after treatment of fracture
Z09.4 [45561611]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.04%
—
—
—
—
—
—
0
7
68
668
Hemoglobin A1c/Hemoglobin.total in Blood
4548-4 [3004410]
3.2e-03
-3.6e-02
—
—
—
2.0e-01
-8.5e-02
cases:28.74%
controls:28.67%
cases:19.54%
controls:20.12%
—
—
—
—
—
—
cases:25.88%
controls:22.32%
cases:44.12%
controls:46.22%
25
248
62
617
17
174
70
691
—
—
—
22
185
63
644
30
312
38
363
Coloscopy
UJF32 [2001305029]
4.0e-01
—
—
—
-1.0e+50
—
—
cases:8.05%
controls:5.55%
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
7
48
80
817
—
—
—
0
5
87
859
—
—
valsartan; oral
C09CA03 [21601826]
-1.0e+50
-1.0e+50
-1.0e+50
—
-1.0e+50
-1.0e+50
-1.0e+50
cases:0.00%
controls:2.43%
cases:0.00%
controls:1.73%
cases:0.00%
controls:0.58%
—
—
cases:0.00%
controls:0.58%
cases:0.00%
controls:1.69%
cases:0.00%
controls:2.96%
0
21
87
844
0
15
87
850
0
5
87
860
—
0
5
87
859
0
14
85
815
0
20
68
655
Influenza virus A+B Ag [Presence] in Specimen
24015-0 [3024891]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
87
857
—
—
—
—
—
—
Destruction of lesion of skin, site unspecified
QXA25 [2001310041]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.74%
—
—
—
—
—
—
0
5
68
670
Limited function/disability (L)
L28 [2002000647]
7.9e-01
—
—
—
—
—
6.6e-01
cases:6.90%
controls:3.24%
—
—
—
—
—
—
—
—
—
—
cases:8.82%
controls:4.74%
6
28
81
837
—
—
—
—
—
6
32
62
643
cromoglicic acid
S01GX01 [21605085]
4.0e-01
1.3e+00
—
—
—
—
—
cases:5.75%
controls:3.93%
cases:5.75%
controls:1.62%
—
—
—
—
—
—
—
—
—
—
5
34
82
831
5
14
82
851
—
—
—
—
—
levomepromazine; oral, parenteral
N05AA02 [21604493]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
87
857
—
—
—
—
—
—
Neurology
13 [38004458]
6.2e-01
—
—
—
—
6.8e-01
2.1e-01
cases:19.54%
controls:11.56%
—
—
—
—
—
—
—
—
cases:8.24%
controls:4.34%
cases:13.24%
controls:10.96%
17
100
70
765
—
—
—
—
7
36
78
793
9
74
59
601
furosemide; oral, parenteral
C03CA01 [21601518]
4.9e-02
1.3e-01
—
—
—
3.3e-01
-3.1e-01
cases:6.90%
controls:6.59%
cases:5.75%
controls:5.09%
—
—
—
—
—
—
cases:8.24%
controls:6.03%
cases:7.35%
controls:9.78%
6
57
81
808
5
44
82
821
—
—
—
7
50
78
779
5
66
63
609
Mugwort IgE Ab [Units/volume] in Serum
6183-8 [3008401]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.69%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
87
859
—
—
—
—
—
—
PEEP
WX722 [2001310825]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.39%
—
—
—
—
—
—
—
—
—
—
—
—
0
12
87
853
—
—
—
—
—
—
Stomatognathic treatment, basic
SHA02 [2001310406]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
0
5
87
860
—
—
—
0
5
85
824
—
lercanidipine; oral
C08CA13 [21601759]
7.6e-01
—
—
—
-1.0e+50
—
—
cases:5.75%
controls:2.77%
—
—
—
—
—
—
cases:0.00%
controls:1.04%
—
—
—
—
5
24
82
841
—
—
—
0
9
87
855
—
—
Insertion of (intrauterine) contraceptive device
Z30.1 [45537626]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
—
—
—
—
—
—
—
—
—
—
0
8
87
857
—
—
—
—
—
Heart failure
I50 [45581779]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.04%
—
—
—
—
—
—
0
7
68
668
Partial excision of meniscus of knee, arthroscopic
NGD05 [2001308109]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.62%
—
—
—
—
—
—
—
—
—
—
—
—
0
14
87
851
—
—
—
—
—
—
fluticasone furoate
R03BA09 [45893496]
5.6e-01
—
-1.0e+50
—
—
—
—
cases:6.90%
controls:4.05%
—
—
cases:0.00%
controls:0.69%
—
—
—
—
—
—
—
—
6
35
81
830
—
0
6
87
859
—
—
—
—
Specific gravity of Urine by Refractometry
5810-7 [3019150]
-2.7e-01
—
—
—
—
8.1e-01
1.3e-01
cases:5.75%
controls:7.40%
—
—
—
—
—
—
—
—
cases:7.06%
controls:3.26%
cases:11.76%
controls:10.52%
5
64
82
801
—
—
—
—
6
27
79
802
8
71
60
604
Acute maxillary sinusitis
J01.0 [45601112]
—
—
—
—
—
-1.0e+50
1.1e+00
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.45%
cases:10.29%
controls:3.70%
—
—
—
—
—
0
12
85
817
7
25
61
650
Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma
33762-6 [3029187]
—
—
—
—
-1.0e+50
—
2.3e-01
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.69%
—
—
cases:14.71%
controls:12.00%
—
—
—
—
0
6
87
858
—
10
81
58
594
Other chest pain
R07.3 [45597166]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.19%
—
—
—
—
—
—
0
8
68
667
Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture
13317-3 [3019902]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.22%
—
—
—
—
—
—
0
15
68
660
Neisseria gonorrhoeae DNA [Presence] in Specimen by NAA with probe detection
24111-7 [3011371]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.78%
—
—
—
—
—
—
0
12
68
663
Human metapneumovirus RNA [Presence] in Specimen by NAA with probe detection
38917-1 [3042194]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
87
860
—
—
—
—
—
—
vilanterol and fluticasone furoate
R03AK10 [43534841]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
0
5
87
859
—
—
flumetasone and antiinfectives
S02CA02 [21605174]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.74%
—
—
—
—
—
—
0
5
68
670
enoxaparin; parenteral
B01AB05 [21600976]
6.1e-01
—
—
—
—
-1.0e+50
1.0e+00
cases:9.20%
controls:5.20%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.57%
cases:10.29%
controls:4.00%
8
45
79
820
—
—
—
—
0
13
85
816
7
27
61
648
Examination for recruitment to armed forces
Z02.3 [45576125]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.92%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.84%
cases:0.00%
controls:1.19%
0
8
87
857
—
—
—
—
0
7
85
822
0
8
68
667
Preventive oral health care
SCA02 [2001310303]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:2.31%
cases:0.00%
controls:1.04%
—
—
—
—
—
—
—
—
—
—
0
20
87
845
0
9
87
856
—
—
—
—
—
lansoprazole; oral
A02BC03 [21600098]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:2.77%
—
—
—
—
—
—
—
—
—
—
—
0
24
87
841
—
—
—
—
—
Informing family of child’s disability
SPAT1236 [2001700337]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.74%
—
—
—
—
—
—
0
5
68
670
Respiratory infection other
R83 [2002000951]
5.3e-01
—
—
—
—
-1.0e+50
-1.3e-01
cases:5.75%
controls:3.47%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.33%
cases:7.35%
controls:8.30%
5
30
82
835
—
—
—
—
0
11
85
818
5
56
63
619
Spinalanesthesia
WX320 [2001310799]
4.6e-01
—
—
—
—
—
—
cases:5.75%
controls:3.70%
—
—
—
—
—
—
—
—
—
—
—
—
5
32
82
833
—
—
—
—
—
—
Other angina pectoris unspecified coronary artery status
I20.89 [2000502401]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
87
860
—
—
—
—
—
—
Erythrocytes [#/volume] in Cerebral spinal fluid
26454-9 [3027475]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.74%
—
—
—
—
—
—
0
5
68
670
Presence of aortocoronary bypass graft
Z95.1 [45556881]
—
-1.0e+50
-1.0e+50
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.69%
cases:0.00%
controls:0.69%
—
—
—
—
cases:0.00%
controls:0.97%
cases:0.00%
controls:1.19%
—
0
6
87
859
0
6
87
859
—
—
0
8
85
821
0
8
68
667
Ferritin [Mass/volume] in Serum or Plasma
2276-4 [3001122]
2.1e-02
—
-1.0e+50
—
-1.0e+50
7.0e-01
2.0e-01
cases:9.20%
controls:9.02%
—
—
cases:0.00%
controls:0.58%
—
—
cases:0.00%
controls:0.93%
cases:10.59%
controls:5.55%
cases:19.12%
controls:16.15%
8
78
79
787
—
0
5
87
860
—
0
8
87
856
9
46
76
783
13
109
55
566
Atrial fibrillation and flutter
I48 [45596206]
3.5e-01
—
—
—
-1.0e+50
6.6e-01
—
cases:8.05%
controls:5.78%
—
—
—
—
—
—
cases:0.00%
controls:0.58%
cases:5.88%
controls:3.14%
—
—
7
50
80
815
—
—
—
0
5
87
859
5
26
80
803
—
Dysuria
R30.0 [45592416]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.89%
—
—
—
—
—
—
0
6
68
669
chlorhexidine
S02AA09 [21605155]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.81%
—
—
—
—
—
—
—
—
—
—
—
0
7
87
858
—
—
—
—
—
Dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide (adults)
285 [2001600217]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.89%
—
—
—
—
—
—
0
6
68
669
Transferrin [Mass/volume] in Serum or Plasma
3034-6 [3004789]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.73%
—
—
—
—
—
—
—
—
—
—
—
0
15
87
850
—
—
—
—
—
Preparing and restoring tooth to enable root canal treatment
SGC40 [2001310398]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.74%
—
—
—
—
—
—
0
5
68
670
Assessment of need for orthodontic treatment
SJF01 [2001310449]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
87
860
—
—
—
—
—
—
Cholesterol non HDL [Moles/volume] in Serum or Plasma
70204-3 [42868678]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
87
854
—
—
—
—
—
—
Postpartum check-up
SPAT1380 [2001700480]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.81%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
87
858
—
—
—
—
—
—
Wrist X-ray examination
ND1AA [2001307576]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.81%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
87
858
—
—
—
—
—
—
salmeterol and fluticasone
R03AK06 [21603280]
7.6e-01
1.2e+00
—
—
—
1.3e+00
8.0e-01
cases:8.05%
controls:3.93%
cases:6.90%
controls:2.20%
—
—
—
—
—
—
cases:7.06%
controls:2.05%
cases:8.82%
controls:4.15%
7
34
80
831
6
19
81
846
—
—
—
6
17
79
812
6
28
62
647
warfarin; oral, parenteral
B01AA03 [21600965]
8.2e-02
—
—
—
—
—
—
cases:5.75%
controls:5.32%
—
—
—
—
—
—
—
—
—
—
—
—
5
46
82
819
—
—
—
—
—
—
buprenorphine; parenteral, sublingual, transdermal
N02AE01 [21604287]
—
—
-1.0e+50
—
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
0
5
87
860
—
0
5
87
859
—
—
melatonin; oral
N05CH01 [21604659]
—
1.4e+00
-1.0e+50
—
-1.0e+50
—
8.3e-01
—
—
cases:5.75%
controls:1.50%
cases:0.00%
controls:0.58%
—
—
cases:0.00%
controls:0.69%
—
—
cases:11.76%
controls:5.48%
—
5
13
82
852
0
5
87
860
—
0
6
87
858
—
8
37
60
638
Polyarthrosis, unspecified
M15.9 [45543481]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.04%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
0
9
87
856
—
—
—
—
0
5
85
824
—
Presence of dental prosthetic device (complete)(partial)
Z97.2 [45542503]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.74%
—
—
—
—
—
—
0
5
68
670
triamcinolone and antiseptics
D07BB03 [21602150]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.81%
—
—
—
—
—
—
—
—
—
—
—
0
7
87
858
—
—
—
—
—
Periodontitis complex
K05.30 [2000502728]
—
—
—
—
—
—
1.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:10.29%
controls:2.37%
—
—
—
—
—
—
7
16
61
659
Monitoring vital functions without anesthesia
WX000 [2001310756]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.27%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.74%
0
11
87
854
—
—
—
—
—
0
5
68
670
ferrous glycine sulfate; oral
B03AA01 [21601080]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.07%
—
0
5
87
860
—
—
—
—
0
14
68
661
amitriptyline and psycholeptics
N06CA01 [21604789]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.74%
—
—
—
—
—
—
0
5
68
670
Thoracic and Cardiac Surgery
OMOP4822009 [45756830]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.81%
—
—
—
—
—
—
—
—
—
—
—
0
7
87
858
—
—
—
—
—
Other somatoform disorders
F45.8 [45600750]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
0
5
85
824
—
zolpidem; oral
N05CF02 [21604655]
9.2e-01
—
—
—
-1.0e+50
—
—
cases:8.05%
controls:3.35%
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
7
29
80
836
—
—
—
0
5
87
859
—
—
Prostate Specific Ag Free [Mass/volume] in Serum or Plasma
10886-0 [3005013]
3.7e-02
—
—
—
—
—
—
cases:5.75%
controls:5.55%
—
—
—
—
—
—
—
—
—
—
—
—
5
48
82
817
—
—
—
—
—
—
aPTT in Platelet poor plasma by Coagulation assay
14979-9 [3018677]
6.7e-01
-1.0e+50
—
—
—
—
—
cases:8.05%
controls:4.28%
cases:0.00%
controls:0.92%
—
—
—
—
—
—
—
—
—
—
7
37
80
828
0
8
87
857
—
—
—
—
—
Neck symptom/complaint
L01 [2002000626]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.97%
—
—
—
—
—
—
—
0
8
85
821
—
Extensive health check-up of children and adolescents
SPAT1316 [2001700417]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
—
0
6
85
823
—
Oral and dental health check by dental hygienist or dental assistant
SAB02 [2001310280]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.04%
—
—
—
—
—
—
0
7
68
668
filgrastim; parenteral
L03AA02 [21603851]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.69%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
87
859
—
—
—
—
—
—
Supraglottic ventilation device
WX702 [2001310818]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.04%
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.74%
0
9
87
856
0
5
87
860
—
—
—
—
0
5
68
670
esomeprazole; oral, parenteral
A02BC05 [21600100]
3.0e-01
—
—
—
-1.0e+50
1.6e-01
3.7e-01
cases:11.49%
controls:8.79%
—
—
—
—
—
—
cases:0.00%
controls:0.81%
cases:5.88%
controls:5.07%
cases:11.76%
controls:8.44%
10
76
77
789
—
—
—
0
7
87
857
5
42
80
787
8
57
60
618
scopolamine, combinations
A04AD51 [21600507]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
—
0
6
85
823
—
Nonorganic insomnia
F51.0 [45552492]
—
-1.0e+50
—
—
—
—
1.0e+00
—
—
cases:0.00%
controls:1.16%
—
—
—
—
—
—
—
—
cases:8.82%
controls:3.41%
—
0
10
87
855
—
—
—
—
6
23
62
652
Mycobacterium tuberculosis stimulated gamma interferon release by CD4+ and CD8+ T-cells [Units/volume] in Blood
88518-6 [36304997]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.74%
—
—
—
—
—
—
0
5
68
670
Other local analgesia
WX199 [2001310775]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.89%
—
—
—
—
—
—
0
6
68
669
Localized swelling, mass and lump, neck
R22.1 [45592412]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.69%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
87
859
—
—
—
—
—
—
Medical observation and evaluation for suspected diseases and conditions, ruled out
Z03 [45552058]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.39%
cases:0.00%
controls:0.69%
—
—
—
—
—
—
—
—
—
—
0
12
87
853
0
6
87
859
—
—
—
—
—
Malaise and fatigue
R53 [45553741]
—
—
—
—
—
—
1.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:11.76%
controls:4.59%
—
—
—
—
—
—
8
31
60
644
Decompression of lumbar nerve roots
ABC36 [2001300475]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.04%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
87
856
—
—
—
—
—
—
Monocytes [#/volume] in Blood
26484-6 [3001604]
2.0e-01
7.2e-01
—
—
—
2.9e-01
4.3e-01
cases:14.94%
controls:12.60%
cases:12.64%
controls:6.59%
—
—
—
—
—
—
cases:8.24%
controls:6.27%
cases:27.94%
controls:20.15%
13
109
74
756
11
57
76
808
—
—
—
7
52
78
777
19
136
49
539
levocetirizine; oral
R06AE09 [21603498]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
—
0
6
85
823
—
Presence of electronic cardiac devices
Z95.0 [45571406]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.19%
—
0
5
87
860
—
—
—
—
0
8
68
667
Hemoglobin [Mass/volume] in Venous blood
30350-3 [3004119]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.81%
—
—
—
—
—
—
—
—
—
—
—
0
7
87
858
—
—
—
—
—
etoricoxib; oral
M01AH05 [21603996]
1.7e-01
8.2e-01
—
—
—
3.1e-01
8.4e-01
cases:19.54%
controls:16.99%
cases:14.94%
controls:7.17%
—
—
—
—
—
—
cases:8.24%
controls:6.15%
cases:30.88%
controls:16.15%
17
147
70
718
13
62
74
803
—
—
—
7
51
78
778
21
109
47
566
Tissue transglutaminase IgA Ab [Units/volume] in Serum
31017-7 [3019050]
3.5e-01
-1.0e+50
—
—
—
—
-1.1e-01
cases:6.90%
controls:4.97%
cases:0.00%
controls:2.08%
—
—
—
—
—
—
—
—
cases:7.35%
controls:8.15%
6
43
81
822
0
18
87
847
—
—
—
—
5
55
63
620
Left ventricular failure
I50.1 [45543181]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
0
5
85
824
—
Pruritus
S02 [2002000967]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.74%
—
—
—
—
—
—
0
5
68
670
Assessment of need for rehabilitation and/or rehabilitation plan
SPAT1220 [2001700321]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.74%
—
—
—
—
—
—
0
5
68
670
Examination of eyes and vision
Z01.0 [45566391]
—
—
—
—
—
—
9.4e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:10.29%
controls:4.30%
—
—
—
—
—
—
7
29
61
646
Paraesthesia of skin
R20.2 [45568120]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.48%
—
—
—
—
—
—
0
10
68
665
Hip symptom/complaint
L13 [2002000637]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.81%
—
—
—
—
—
—
—
—
—
—
—
0
7
87
858
—
—
—
—
—
Coxarthrosis, unspecified
M16.9 [45591742]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
0
5
87
860
—
—
—
—
—
Anaemia other/unspecified
B82 [2002000293]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.74%
—
—
—
—
—
—
0
5
68
670
Basocellular carcinoma of the skin on another or unspecified part of the face
C44.31 [2000500792]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:1.39%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
cases:0.00%
controls:1.19%
0
12
87
853
—
—
—
—
0
5
85
824
0
8
68
667
Balanoposthitis
N48.1 [45567850]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.04%
—
—
—
—
—
—
0
7
68
668
Congestive heart failure
I50.0 [45567179]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.04%
cases:0.00%
controls:0.81%
—
—
—
—
—
—
—
—
—
—
0
9
87
856
0
7
87
858
—
—
—
—
—
Platelets [#/volume] in Blood
26515-7 [3007461]
1.5e-01
4.2e-01
2.5e-01
—
7.4e-01
3.0e-01
3.4e-01
cases:50.57%
controls:46.82%
cases:47.13%
controls:36.99%
cases:10.34%
controls:8.21%
—
—
cases:18.39%
controls:9.72%
cases:47.06%
controls:39.81%
cases:75.00%
controls:68.15%
44
405
43
460
41
320
46
545
9
71
78
794
—
16
84
71
780
40
330
45
499
51
460
17
215
pH of Serum or Plasma
2753-2 [3018418]
6.1e-01
—
-1.0e+50
—
—
1.0e+00
-2.4e-02
cases:11.49%
controls:6.59%
—
—
cases:0.00%
controls:0.69%
—
—
—
—
cases:5.88%
controls:2.17%
cases:10.29%
controls:10.52%
10
57
77
808
—
0
6
87
859
—
—
5
18
80
811
7
71
61
604
Nephrology
39 [38004479]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.48%
—
—
—
—
—
—
0
10
68
665
Heartburn
R12 [45539318]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
0
5
87
860
—
—
—
—
—
Fetal Trisomy 21 risk [Likelihood] Based on maternal age
49090-4 [3049207]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.33%
—
—
—
—
—
—
0
9
68
666
Chronic maxillary sinusitis
J32.0 [45586667]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.89%
—
—
—
—
—
—
0
6
68
669
Lower uterine segment caesarean section
MCA10 [2001306959]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.81%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
87
858
—
—
—
—
—
—
Adjustment or review of hearing aid
DAX00 [2001301528]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.81%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.33%
0
7
87
858
—
—
—
—
—
0
9
68
666
Other gastroenteritis and colitis of infectious and unspecified origin
A09 [45605189]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
—
0
6
85
823
—
Haptoglobin [Mass/volume] in Serum or Plasma
4542-7 [3012336]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.81%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
87
858
—
—
—
—
—
—
Hyaline casts [#/volume] in Urine by Automated count
51484-4 [3030981]
—
—
—
—
—
—
8.1e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.35%
controls:3.41%
—
—
—
—
—
—
5
23
63
652
Follow-up examination after surgery for other conditions
Z09.0 [45576131]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
87
860
—
—
—
—
—
—
Medical doctor
Z2221 [2001311556]
4.2e-01
—
—
—
—
—
1.3e+00
cases:8.05%
controls:5.43%
—
—
—
—
—
—
—
—
—
—
cases:7.35%
controls:2.07%
7
47
80
818
—
—
—
—
—
5
14
63
661
Periodontal treatment
SDA03 [2001310328]
6.0e-01
6.2e-01
—
—
—
—
5.8e-01
cases:14.94%
controls:8.79%
cases:6.90%
controls:3.82%
—
—
—
—
—
—
—
—
cases:19.12%
controls:11.70%
13
76
74
789
6
33
81
832
—
—
—
—
13
79
55
596
Vaccination
SPAT1325 [2001700426]
2.0e-01
—
—
—
—
—
—
cases:8.05%
controls:6.71%
—
—
—
—
—
—
—
—
—
—
—
—
7
58
80
807
—
—
—
—
—
—
CBC panel - Blood by Automated count
58410-2 [40761511]
9.5e-02
-4.4e-01
—
—
—
-3.7e-01
-6.3e-02
cases:42.53%
controls:40.23%
cases:18.39%
controls:25.90%
—
—
—
—
—
—
cases:20.00%
controls:26.66%
cases:52.94%
controls:54.52%
37
348
50
517
16
224
71
641
—
—
—
17
221
68
608
36
368
32
307
mometasone, combinations
R01AD59 [947911]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.89%
—
—
—
—
—
—
0
6
68
669
Visual field testing with Octopus automated perimetry
CS444 [2001301477]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
87
860
—
—
—
—
—
—
diclofenac; oral, parenteral, rectal
M01AB05 [21603945]
1.5e-01
-4.8e-02
—
—
-1.0e+50
2.6e-01
1.8e-01
cases:16.09%
controls:14.22%
cases:5.75%
controls:6.01%
—
—
—
—
cases:0.00%
controls:0.58%
cases:7.06%
controls:5.55%
cases:14.71%
controls:12.59%
14
123
73
742
5
52
82
813
—
—
0
5
87
859
6
46
79
783
10
85
58
590
Detailed ultrasound examination of fetus including color doppler method
MA2DE [2001306835]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
87
860
—
—
—
—
—
—
dexbrompheniramine, combinations
R06AB56 [21603469]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
—
0
6
85
823
—
Root filling of tooth with one root canal
SGB10 [2001310388]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:2.20%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.22%
0
19
87
846
—
—
—
—
—
0
15
68
660
Acute sinusitis, unspecified
J01.9 [45543252]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
87
860
—
—
—
—
—
—
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
R5110 [2001310246]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.84%
—
—
—
—
—
—
—
0
7
85
822
—
Comprehensive monitoring of chronic illness
SPAT1250 [2001700351]
—
—
-1.0e+50
—
—
—
-5.0e-02
—
—
—
—
cases:0.00%
controls:1.16%
—
—
—
—
—
—
cases:7.35%
controls:7.70%
—
—
0
10
87
855
—
—
—
5
52
63
623
Place of Employment-Worksite
18 [581475]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.89%
—
—
—
—
—
—
0
6
68
669
Eyelid symptom/complaint
F16 [2002000407]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.69%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
87
859
—
—
—
—
—
—
C reactive protein [Mass/volume] in Body fluid
16503-5 [3035320]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.89%
—
—
—
—
—
—
0
6
68
669
clopidogrel; oral
B01AC04 [21600989]
3.7e-02
—
—
—
-1.0e+50
—
—
cases:5.75%
controls:5.55%
—
—
—
—
—
—
cases:0.00%
controls:0.69%
—
—
—
—
5
48
82
817
—
—
—
0
6
87
858
—
—
Lambda light chains.free [Mass/volume] in Serum or Plasma
33944-0 [3047169]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.19%
—
—
—
—
—
—
0
8
68
667
Sinusitis acute/chronic
R75 [2002000943]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
87
860
—
—
—
—
—
—
insulins and analogues for injection, intermediate-acting - combinations; parenteral
A10AC30 [21600727]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.69%
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.74%
0
6
87
859
0
5
87
860
—
—
—
—
0
5
68
670
Acute tubulo-interstitial nephritis
N10 [45543856]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.04%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
87
856
—
—
—
—
—
—
Systemic arterial pressure
364090009 [4238447]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
87
860
—
—
—
—
—
—
Periodontal treatment, brief
SDA02 [2001310327]
-3.7e-01
1.0e+00
—
—
—
—
5.2e-01
cases:5.75%
controls:8.09%
cases:5.75%
controls:2.20%
—
—
—
—
—
—
—
—
cases:17.65%
controls:11.26%
5
70
82
795
5
19
82
846
—
—
—
—
12
76
56
599
Cholesterol in HDL [Moles/volume] in Serum or Plasma
14646-4 [3023602]
-1.4e-01
1.3e-01
—
—
—
3.3e-01
-6.8e-02
cases:33.33%
controls:36.42%
cases:22.99%
controls:20.81%
—
—
—
—
—
—
cases:27.06%
controls:21.11%
cases:50.00%
controls:51.70%
29
315
58
550
20
180
67
685
—
—
—
23
175
62
654
34
349
34
326
Simple adjuvant cytostatic therapy
WB103 [2001310627]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.81%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
87
858
—
—
—
—
—
—
Examination for driving licence
Z02.4 [45552056]
5.1e-01
—
—
—
—
—
1.3e-01
cases:8.05%
controls:4.97%
—
—
—
—
—
—
—
—
—
—
cases:7.35%
controls:6.52%
7
43
80
822
—
—
—
—
—
5
44
63
631
Collection duration of Urine
13362-9 [3016750]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.89%
—
—
—
—
—
—
0
6
68
669
Shigella sp [Presence] in Stool by Culture
82300-5 [42529406]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.69%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
87
859
—
—
—
—
—
—
ondansetron; oral, parenteral, rectal
A04AA01 [21600493]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.04%
cases:0.00%
controls:0.69%
—
—
—
—
—
—
—
—
—
—
0
9
87
856
0
6
87
859
—
—
—
—
—
Impacted cerumen
H61.2 [45562307]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.78%
—
—
—
—
—
—
0
12
68
663
Natriuretic peptide B [Mass/volume] in Serum or Plasma
30934-4 [3011960]
—
—
—
—
—
—
1.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.82%
controls:2.96%
—
—
—
—
—
—
6
20
62
655
Sleep apnoea
G47.3 [45562094]
—
—
—
—
—
—
5.3e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:11.76%
controls:7.26%
—
—
—
—
—
—
8
49
60
626
25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Moles/volume] in Serum or Plasma
68438-1 [40771025]
-6.3e-03
—
-1.0e+50
—
—
9.3e-01
2.2e-01
cases:9.20%
controls:9.25%
—
—
cases:0.00%
controls:0.58%
—
—
—
—
cases:10.59%
controls:4.46%
cases:19.12%
controls:16.00%
8
80
79
785
—
0
5
87
860
—
—
9
37
76
792
13
108
55
567
Achilles tendinitis
M76.6 [45596682]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
87
860
—
—
—
—
—
—
Normoblasts [#/volume] in Blood
715-3 [3021589]
-1.4e-01
1.1e-01
—
—
—
-1.5e-01
4.6e-01
cases:8.05%
controls:9.13%
cases:8.05%
controls:7.28%
—
—
—
—
—
—
cases:5.88%
controls:6.76%
cases:26.47%
controls:18.52%
7
79
80
786
7
63
80
802
—
—
—
5
56
80
773
18
125
50
550
Trochanteric bursitis
M70.6 [45606304]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.45%
—
—
—
—
—
—
—
0
12
85
817
—
Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma
2324-2 [3026910]
-2.9e-01
-2.6e-01
—
—
—
4.9e-02
-2.5e-02
cases:16.09%
controls:20.35%
cases:6.90%
controls:8.79%
—
—
—
—
—
—
cases:10.59%
controls:10.13%
cases:26.47%
controls:26.96%
14
176
73
689
6
76
81
789
—
—
—
9
84
76
745
18
182
50
493
Counselling/guidance promoting independent living
SPAT1222 [2001700323]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.21%
—
—
—
—
—
—
—
0
10
85
819
—
Care involving use of rehabilitation procedure, unspecified
Z50.9 [45595525]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
0
5
85
824
—
other preparations, combinations; ointment
C05AX03 [21601631]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.16%
—
—
—
—
—
—
—
—
—
—
—
0
10
87
855
—
—
—
—
—
SMOKING - SMOKE2: yes - SMOKE3: current - SMOKE5: Unspecified
SMOKING-1-1-0 [2002330116]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
—
—
—
—
—
—
—
—
—
—
0
8
87
857
—
—
—
—
—
naproxcinod
M01AE18 [40254094]
-3.1e-02
4.6e-01
—
—
—
—
4.7e-01
cases:10.34%
controls:10.64%
cases:5.75%
controls:3.70%
—
—
—
—
—
—
—
—
cases:10.29%
controls:6.67%
9
92
78
773
5
32
82
833
—
—
—
—
7
45
61
630
chloramphenicol
S01AA01 [21603554]
8.5e-01
—
—
—
—
6.0e-01
2.3e-01
cases:19.54%
controls:9.36%
—
—
—
—
—
—
—
—
cases:7.06%
controls:3.98%
cases:14.71%
controls:12.00%
17
81
70
784
—
—
—
—
6
33
79
796
10
81
58
594
Oxygen [Partial pressure] adjusted to patient's actual temperature in Venous blood
19258-3 [3004529]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.67%
—
—
—
—
—
—
0
18
68
657
Triglyceride [Moles/volume] in Serum or Plasma
14927-8 [3025839]
6.4e-01
—
—
—
—
7.7e-01
-1.2e-01
cases:5.75%
controls:3.12%
—
—
—
—
—
—
—
—
cases:7.06%
controls:3.38%
cases:11.76%
controls:13.04%
5
27
82
838
—
—
—
—
6
28
79
801
8
88
60
587
Excessive and frequent menstruation with regular cycle
N92.0 [45577544]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.89%
—
—
—
—
—
—
0
6
68
669

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
33
135
3.31
6.44
4.3
3.2
74.55
428.41
ng/l
0.85
19
98
15
57
2.97
3.15
2.7
2.3
1.76
5.83
ug/l
3.33
15
51
11
41
2.92
2.30
6.5
2.1
217.23
119.42
ng/l
0.51
11
36
61
472
1.95
2.17
7.0
11.4
4.13
3.95
e9/l
0.21
54
415
69
569
1.98
1.88
4.1
4.3
14.43
14.79
pmol/l
0.52
64
519
83
753
2.80
1.67
20.0
15.2
23.61
23.25
mg/l
0.03
68
627
16
86
2.05
1.63
1.8
2.7
5.81
6.09
umol/l
0.07
16
75
32
226
1.65
1.38
2.5
2.1
116.84
177.87
u/l
0.97
32
221
42
318
1.61
1.37
2.3
2.1
100.97
97.47
pmol/l
0.24
23
169
36
263
1.62
1.36
3.6
3.3
31.51
65.55
e6/l
0.63
29
203
8
36
2.34
1.28
1.3
1.2
—
—
—
0
0
21
138
1.69
1.17
1.2
1.3
20.26
6.25
u/ml
—
9
52
38
295
1.51
1.05
4.7
3.9
30.54
81.35
e6/l
0.51
28
208
34
258
1.52
1.04
2.4
2.5
—
—
—
0
0
35
269
1.50
1.01
4.7
5.7
—
—
—
0
0
0
28
0.00
0.99
0.0
1.2
—
—
—
0
0
29
215
1.52
0.98
3.0
3.0
—
—
—
0
0
57
487
1.48
0.95
5.0
4.2
—
50.78
—
0
9
29
217
1.50
0.94
3.5
3.2
0.65
0.22
e6/l
0.60
21
158
45
370
1.44
0.90
2.9
2.7
—
—
estimate
—
0
0
33
256
1.46
0.89
3.3
4.1
9.90
13.05
mg/mmol
0.21
21
160
15
97
1.66
0.88
2.1
1.6
—
—
—
0
0
32
249
1.45
0.85
3.3
3.4
50.73
75.69
mg/l
0.41
21
166
18
124
1.57
0.83
1.8
2.0
—
—
—
0
0
15
99
1.62
0.82
1.1
1.3
—
—
—
0
0
15
99
1.62
0.82
1.1
1.3
—
—
—
0
0
36
433
0.71
0.77
5.3
3.8
0.00
0.00
estimate
—
6
90
18
245
0.67
0.76
4.4
3.9
0.00
0.01
estimate
—
6
83
7
39
1.86
0.74
1.0
1.1
—
—
—
0
0
52
452
1.37
0.69
6.8
4.8
6.79
6.57
mmol/l
0.29
47
425
25
315
0.71
0.69
3.2
3.2
—
—
—
0
0
50
434
1.35
0.66
4.2
6.1
0.55
0.57
e9/l
0.22
44
374
50
434
1.35
0.66
4.2
6.1
0.04
0.04
e9/l
0.26
44
371
36
423
0.75
0.62
5.2
3.8
0.00
0.00
estimate
—
6
96
14
98
1.51
0.61
1.4
1.5
—
—
—
0
0
0
21
0.00
0.61
0.0
1.2
—
—
—
0
0
36
422
0.75
0.60
5.2
3.8
0.00
0.00
estimate
—
6
93
0
22
0.00
0.60
0.0
2.5
—
4.04
—
0
11
6
35
1.77
0.59
1.2
2.0
41.50
38.23
nmol/l
—
6
35
11
74
1.56
0.56
5.9
9.7
—
—
—
0
0
6
38
1.62
0.55
1.2
1.3
—
—
—
0
0
75
788
0.67
0.54
16.6
13.3
—
—
—
0
0
26
313
0.76
0.51
4.6
3.4
41.57
45.83
ng/l
0.08
17
214
7
47
1.53
0.49
1.1
1.4
—
—
—
0
0
25
204
1.31
0.48
3.6
3.1
—
—
estimate
—
0
0
7
49
1.46
0.47
1.1
1.4
—
—
—
0
0
7
49
1.46
0.47
1.1
1.4
—
—
—
0
0
7
49
1.46
0.47
1.1
1.4
—
—
—
0
0
8
55
1.50
0.44
5.5
8.9
22.54
25.19
mmol/l
—
8
55
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
0
16
0.00
0.41
0.0
1.9
—
—
—
0
0
0
16
0.00
0.41
0.0
1.1
—
—
—
0
0
5
34
1.50
0.41
3.6
1.9
—
—
—
0
0
0
19
0.00
0.39
0.0
4.3
—
27.73
—
0
13
21
172
1.29
0.39
1.1
1.5
2.84
2.42
g/l
0.29
11
101
6
41
1.50
0.37
1.2
2.1
—
—
—
0
0
28
240
1.24
0.36
5.2
6.1
—
—
—
0
0
6
90
0.64
0.34
1.5
1.3
—
—
—
0
0
24
204
1.24
0.33
3.2
5.1
—
—
—
0
0
35
312
1.20
0.31
2.6
2.0
—
—
—
0
0
7
55
1.30
0.31
3.1
3.3
24.14
24.21
mmol/l
—
7
55
12
94
1.32
0.30
6.6
8.9
7.42
7.42
ph
—
7
52
9
117
0.74
0.29
4.0
2.9
28.56
22.60
%
—
9
109
83
807
1.50
0.27
25.0
19.4
76.36
78.18
umol/l
0.32
83
796
10
78
1.32
0.25
1.4
1.6
—
—
—
0
0
18
153
1.22
0.25
1.7
2.0
—
—
—
0
0
15
177
0.82
0.23
3.3
2.9
0.68
0.69
ug/l
—
9
110
10
80
1.28
0.21
2.7
2.6
0.32
0.18
e6/l
—
10
75
0
10
0.00
0.21
0.0
3.0
—
106.20
—
0
10
0
10
0.00
0.21
0.0
3.0
—
1.19
—
0
10
0
10
0.00
0.21
0.0
3.0
—
4.03
—
0
10
0
12
0.00
0.21
0.0
1.5
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.6
—
—
—
0
0
6
47
1.30
0.21
1.2
1.4
—
—
—
0
0
0
13
0.00
0.21
0.0
1.4
—
1.25
—
0
8
0
13
0.00
0.21
0.0
1.4
—
—
—
0
0
0
14
0.00
0.20
0.0
1.5
—
—
—
0
0
11
132
0.81
0.20
3.5
2.8
12.78
13.40
umol/l
0.11
11
120
11
131
0.82
0.18
1.9
1.6
—
—
—
0
0
7
60
1.18
0.18
1.7
2.1
10.41
9.51
g/l
—
7
51
12
103
1.19
0.14
1.9
1.5
—
—
—
0
0
8
96
0.82
0.14
1.9
1.7
—
—
—
0
0
40
377
1.11
0.14
8.8
11.5
0.00
0.00
e9/l
0.32
32
303
11
127
0.85
0.13
3.0
2.7
2.03
2.28
g/l
1.02
11
113
54
519
1.10
0.13
5.5
4.3
—
—
—
0
0
5
44
1.14
0.10
6.2
4.0
—
—
—
0
0
5
62
0.79
0.08
7.4
4.3
71.20
85.79
ng/l
—
5
55
10
88
1.15
0.08
1.3
2.1
290.50
411.07
nmol/l
—
10
83
12
133
0.89
0.08
3.3
3.0
0.78
0.81
mmol/l
0.44
12
124
6
71
0.83
0.08
1.0
1.2
—
—
—
0
0
8
74
1.09
0.08
1.4
1.2
—
—
—
0
0
7
81
0.85
0.07
1.6
1.8
—
—
—
0
0
34
328
1.06
0.05
7.6
6.7
1.20
1.21
mmol/l
0.20
34
308
10
109
0.91
0.04
6.8
8.8
106.00
104.20
mmol/l
—
10
109
10
93
1.08
0.02
2.6
3.2
2.15
1.79
%
—
10
81
20
206
0.96
0.00
5.0
4.7
—
—
—
0
0
11
108
1.02
0.00
6.5
6.9
1.03
1.09
mmol/l
0.48
11
100
12
122
0.98
0.00
1.6
1.4
240.00
345.71
titre
—
5
28
34
339
1.00
0.00
4.0
3.4
5.93
6.23
ph
0.91
20
187
23
226
1.02
0.00
1.1
1.5
—
—
—
0
0
20
196
1.03
0.00
1.2
1.4
1.13
0.95
u/ml
—
6
62
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.7
—
0.67
—
0
6
0
6
0.00
-0.00
0.0
3.2
—
16.50
—
0
6
6
66
0.90
-0.00
1.5
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.8
—
41.00
—
0
9
0
9
0.00
-0.00
0.0
1.3
—
108.11
—
0
9
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
13.1
—
903.14
—
0
7
0
6
0.00
-0.00
0.0
5.8
—
0.56
—
0
6
0
6
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
4.0
—
48.24
—
0
5
0
9
0.00
-0.00
0.0
1.9
—
—
—
0
0
0
7
0.00
-0.00
0.0
6.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.0
—
16.42
—
0
5
23
230
1.00
-0.00
3.3
2.8
—
0.29
—
0
7
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
7
0.00
-0.00
0.0
4.3
—
0.94
—
0
7
0
7
0.00
-0.00
0.0
25.4
—
1509.57
—
0
7

Mortality – FinRegistry

↥

This endpoint is excluded from FinRegistry analyses (omitted endpoint).

Relationships between endpoints

↥

Index endpoint: Z21_UPPER_ARM – Upper arm

GWS hits: -

This endpoint is excluded from FinRegistry analyses (omitted endpoint).